A Study of the Novel Drug Dimebon in Patients With Huntington's Disease
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety of 3 months of Dimebon dosing and the efficacy of Dimebon
in improving cognitive, motor, and overall function in subjects with Huntington's Disease.